Details of the Drug Combination

General Information of Drug Combination (ID: DCHH2QQ)

Drug Combination Name
Heparin Heparin
Indication
Disease Entry Status REF
STEMI - ST Elevation Myocardial Infarction Phase 4 [1]
Component Drugs Heparin   DM4ZP3W Heparin   DM4ZP3W
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL is unavailable 3D MOL is unavailable

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
COVID-19 DCKVQ54 N. A. Phase 4 [5]
COVID-19 DC17N1X N. A. Phase 4 [6]
COVID-19 DC6VD2X N. A. Phase 4 [5]
COVID-19 DCNBN4B N. A. Phase 1 [7]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT03664180) Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
2 Heparin FDA Label
3 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 090809.
4 Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg Microbes Infect. 2020 Dec;9(1):727-732.
5 ClinicalTrials.gov (NCT04406389) Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial)
6 ClinicalTrials.gov (NCT04409834) Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial
7 ClinicalTrials.gov (NCT05224388) Evaluating Dose Regimen of Intravenous Unfractionated Heparin and Low Molecular Weight Heparin in Critical Ill Patients Versus Critical Ill COVID-19 Patients Using Anti-Xa Levels.